Cover Image

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry

AbstractBackground The impact of psoriasis in special areas (i.e., scalp, nails, palms, soles, genitals) on patient physical functioning, health-related quality of life (HRQoL), and work abilities has not been fully characterized. We assessed associations between disease severity and special area in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bruce Strober (Author), Kristina Callis Duffin (Author), Mark Lebwohl (Author), Adam Sima (Author), Jud Janak (Author), Manish Patel (Author), Huzefa Photowala (Author), Vishvas Garg (Author), Jerry Bagel (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry
by: Andrew Blauvelt, et al.
Published: (2024)

Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry
by: Philip J. Mease, et al.
Published: (2024)

Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
by: Robert R. McLean, et al.
Published: (2023)

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
by: Mark Lebwohl, et al.
Published: (2024)

Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry
by: Robert R. McLean, et al.
Published: (2023)

History of diabetes is associated with reduced likelihood of achieving PASI75 and PASI90 at 12 months among psoriasis patients treated with biologics: A prospective analysis in the CorEvitas Psoriasis Registry
by: Clinton W. Enos, MD, MS, et al.
Published: (2024)

Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry
by: Jonathan I. Silverberg, MD, PhD, MPH, et al.
Published: (2024)

Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry
by: Jonathan I. Silverberg, et al.
Published: (2023)

Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry
by: Jonathan I. Silverberg, et al.
Published: (2024)

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
by: Jonathan I. Silverberg, et al.
Published: (2023)

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States
by: Jashin J. Wu, et al.
Published: (2023)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
by: Grace C. Brummer, BS, et al.
Published: (2017)

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA
by: Walsh JA, et al.
Published: (2018)

Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States
by: April W. Armstrong, et al.
Published: (2023)

Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis
by: Jerry Bagel, et al.
Published: (2020)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018)

Exploring the Chronic Nature of Generalized Pustular Psoriasis [Podcast]
by: Elewski B, et al.
Published: (2024)

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
by: Neil J. Korman, et al.
Published: (2024)

Periods till psoriatic arthritis onset and diagnosis in Russian patients with moderate to severe psoriasis (according to psoriasis patient registry)
by: Alexey A. Kubanov, et al.
Published: (2023)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2024)

Psoriasis in Norway: A Prescription-based Registry Study of Incidence and Prevalence
by: Silje Michelsen Solberg
Published: (2023)

[Translated article] Prevalence of Psoriasis in Colombia According to the National Health Registry
by: D.G. Fernández-Ávila, et al.
Published: (2022)

Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007-2016)
by: Azura Mohd Affandi, et al.
Published: (2018)

Erythrodermic Psoriasis Has Become Less Frequent: Results From the Biobadaderm Registry
by: R. Rivera-Diaz, et al.
Published: (2023)

Linear Psoriasis
by: Agarwalla Arun, et al.
Published: (2001)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
by: Nora Koutruba, et al.
Published: (2010)

Psoriasis herpeticum due to Varicella zoster virus: A Kaposi's varicelliform eruption in erythrodermic psoriasis
by: Geeta Garg, et al.
Published: (2012)

Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study
by: Aino Vesikansa, et al.
Published: (2023)

Impact of Bariatric Surgery on Moderate to Severe Psoriasis: A Retrospective Nationwide Registry Study
by: Marta Laskowski, et al.
Published: (2021)

Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
by: Julia-Tatjana Maul, et al.
Published: (2024)

[Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
by: L.M. Nieto Benito, et al.
Published: (2022)

Patinetes, no todo se evita con el casco
by: Juan Hidalgo Sanz, et al.
Published: (2020)

Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: Palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis
by: Nilendu Sarma
Published: (2017)

New onset and exacerbation of psoriasis after COVID-19 vaccination
by: Nancy Wei, BA, et al.
Published: (2022)

Predictive model and classification for psoriatic arthritis risk assessment for Russian patients with psoriasis (on registry data)
by: Elena V. Bogdanova
Published: (2023)

Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry
by: Tamara W. van Hal, et al.
Published: (2024)

Prevalence and incidence of patients with generalized pustular psoriasis in Denmark-A nationwide registry‐based study
by: Jeanette Halskou Haugaard, et al.
Published: (2023)

H1N1 - É POSSIVEL EVITÁ-LA
by: Nara da Silva
Published: (2017)

Hipotermia no período intra-operatório: é possível evitá-la?
by: Vanessa de Brito Poveda, et al.
Published: (2011)

Hipotermia no período intra-operatório: é possível evitá-la?
by: Vanessa de Brito Poveda, et al.